Panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab for high-risk proliferative diabetic retinopathy

Acta Ophthalmologica

Volumn 89, Issue 7, 2011, Pages

  Filho, José A R ^a   Messias, André ^a   Almeida, Felipe P P ^a   Ribeiro, Jefferson A S ^a   Costa, Rogério A ^a   Scott, Ingrid U ^b   Jorge, Rodrigo ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

angiogenesis; diabetes; laser treatment; vascular endothelial growth factor

Indexed keywords

FLUORESCEIN; RANIBIZUMAB;

ADULT; ARTICLE; CENTRAL SUBFIELD MACULAR THICKNESS; CLINICAL ARTICLE; CONJUNCTIVAL HEMORRHAGE; CONTROLLED STUDY; DIABETIC RETINOPATHY; ENDOPHTHALMITIS; EYE TOXICITY; FEMALE; FLUORESCENCE ANGIOGRAPHY; HIGH RISK PATIENT; HUMAN; INTERMETHOD COMPARISON; INTRAOCULAR FOREIGN BODY; LASER COAGULATION; MALE; OPTICAL COHERENCE TOMOGRAPHY; PANRETINAL PHOTOCOAGULATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RETINA MACULA EDEMA; UVEITIS; VISUAL ACUITY; VISUAL SYSTEM PARAMETERS;

ANTIBODIES, MONOCLONAL, HUMANIZED; CAPILLARY PERMEABILITY; COMBINED MODALITY THERAPY; DIABETIC RETINOPATHY; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; HUMANS; INTRAVITREAL INJECTIONS; LASER COAGULATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETINAL NEOVASCULARIZATION; SINGLE-BLIND METHOD; TOMOGRAPHY, OPTICAL COHERENCE; VISUAL ACUITY;

EID: 80255133183     PISSN: 1755375X     EISSN: 17553768     Source Type: Journal    
DOI: 10.1111/j.1755-3768.2011.02184.x     Document Type: Article

References (37)

1. Adamis AP, Miller JW, Bernal MT, et al., (1994): Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 118: 445-450. (Pubitemid 24307211)
2. Adamis AP, Shima DT, Tolentino MJ, et al., (1996): Inhibition of vascular endothelial growth factor prevents retinal ischemia associated iris neovascularization in a nonhuman primate. Arch Ophthalmol 114: 66-71. (Pubitemid 26026196)
3. Adamis AP, Altaweel M, Bressler NM, et al., (2006): Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. Ophthalmology 113: 23-28. (Pubitemid 43021723)
4. Aiello LP, Avery RL, Arrigg PG, et al., (1994): Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331: 1480-1487. (Pubitemid 24356306)
5. Aiello LP, Pierce EA, Foley ED, et al., (1995): Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA 92: 10457-10461.
6. Avery RL, (2006): Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina 26: 352-354. (Pubitemid 44318195)
7. Avery RL, Pearlsman J, Pieramici DJ, et al., (2006): Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 113: 1695.e1-1695.e15
8. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, &, Singh RJ, (2007): Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 114: 2179-2182. (Pubitemid 350181137)
9. Browning DJ, Fraser CM, &, Clark S, (2008): The relationship of macular thickness to clinically graded diabetic retinopathy severity in eyes without clinically detected diabetic macular edema. Ophthalmology 115: 533-539.
10. Chobanian AV, Bakris GL, Black HR, et al., (2003): National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 289: 2560-2572. (Pubitemid 37430158)
11. Chun DW, Heier JS, Topping TM, et al., (2006): Pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. Ophthalmology 113: 1707-1712.
12. Chylack LT, Wolfe JK, Singer DM, et al., (1993): The lens opacities classification system III. Arch Ophthalmol 111: 831-836. (Pubitemid 23170599)
13. Cunningham ET Jr, Adamis AP, Altaweel M, et al., (2005): A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 112: 1747-1757.
14. Diabetic Retinopathy Clinical Research Network (2010): Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 117: 1064-1077.
15. Early Treatment Diabetic Retinopathy Study Research Group (1985): Photocoagulation for diabetic macular edema. ETDRS report number 1. Arch Ophthalmol 103: 1796-1806.
16. Early Treatment Diabetic Retinopathy Study Research Group (1987): Techniques for scatter and local photocoagulation treatment of diabetic retinopathy: ETDRS Report number 3. Int Ophthalmol Clin 27: 254-264.
17. Early Treatment Diabetic Retinopathy Study Research Group (1991a): Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Ophthalmology 98: 766-785.
18. Early Treatment Diabetic Retinopathy Study Research Group (1991b): Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Ophthalmology 98: 823-833.
19. Emmanuele N, Sacks J, Klein R, et al., (2005): Veterans affairs diabetes trial group. Diabetes Care 28: 1954-1958.
20. Flynn HW Jr, Chew EY, Simons BD, et al., (1992): Pars plana vitrectomy in the early treatment diabetic retinopathy study. ETDRS report number 17. Ophthalmology 99: 1351-1357.
21. Folkman J, (1971): Tumor angiogenesis: therapeutic implications. N Engl J Med 285: 1182-1186.
22. Grant MB, Mames RN, Fitzgerald C, et al., (2000): The efficacy of ocreotide in the therapy of severe nonproliferativeand early proliferative diabetic retinopathy: a randomized controlled study. Diabetes Care 23: 504-509. (Pubitemid 30185795)
23. Iturralde D, Spaide RF, Meyerle CB, et al., (2006): Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina 26: 279-284. (Pubitemid 44318180)
24. Jorge R, Costa RA, Calucci D, et al., (2006): Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study). Retina 26: 1006-1013. (Pubitemid 44973219)
25. Jorge R, Oliveira RS, Messias A, Almeida FP, Strambe ML, Costa RA, &, Scott IU, (2011): Ranibizumab for retinal neovascularization. Ophthalmology 118: 1004-1005.
26. Klein R, (1992): Retinopathy in a population-based study. Trans Am Ophthalmol Soc 90: 561-594. (Pubitemid 23048912)
27. Malecaze F, Clamens S, Simorre-Pinatel V, et al., (1994): Detection of vascular endothelial growth factor messenger RNA and vascular endothelial growth factor-like activity in proliferative diabetic retinopathy. Arch Ophthalmol 112: 1476-1482. (Pubitemid 24350514)
28. Mason JO, Nixon PA, &, White MF, (2006): Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol 142: 685-688. (Pubitemid 44442055)
29. Matsuyama K, Ogata M, Jo N, et al., (2009): Levels of vascular endothelial growth factor and pigment epithelium-derived factor in eyes before and after intravitreal injection of bevacizumab. Jpn J Ophthalmol 53: 243-248.
30. Ramalho LH, Avila MP, Moraes Júnior HV, &, Damasceno Ede F, (2009): Subclinical diabetic macular edema and mild non-proliferative diabetic retinopathy: data correlation with the retinal thickness analyzer (RTA)]. Arq Bras Oftalmol 72: 503-508.
31. Ribeiro JAS, Messias AMV, Scott IU, et al., (2009): Alternative technique for reducing compound waste during intravitreal injections. Arq Bras Oftalmol 72: 641-644.
32. Sawada O, Kawamura H, Kakinoki M, et al., (2007): Vascular endothelial growth factor in áqüeos humor before and after intravitreal injection of bevacizumab in eyes with diabetic retinopathy. Arch Ophthalmol 125: 1363-1366. (Pubitemid 47606601)
33. Spaide RF, &, Fisher YL, (2006): Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 26: 275-278. (Pubitemid 44318179)
34. The diabetic retinopathy study Research Group (1979): Four risk factors for severe visual loss in diabetic retinopathy. The third report from the diabetic retinopathy study. Arch Ophthalmol 97: 654-655.
35. Tonello M, Costa RA, Almeida FPP, Barbosa JC, Scott IU, &, Jorge R, (2007): Panretinal photocoagulation versus PRPplus intravitreal bevacizumab for high-risk proliferative diabetic retinopathy (IBeHi study). Acta Opthalmol 86: 385-389.
36. Vander JF, Duker JS, Benson WE, et al., (1991): Long-term stability and visual outcome after favorable initial response of proliferative diabetic retinopathy to panretinal photocoagulation. Ophthalmology 98: 1575-1579.
37. Zhang XS, Wang JJ, Gao G, et al., (2006): Pigment epithelium-derived factor downregulates vascular endothelial growth factor (VEGF) expression an inhibits VEGF-VEGF receptor 2 binding in diabetic retinopathy. J Mol Endocrinol 37: 1-12. (Pubitemid 44288601)